Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant

AIMS: High dose melphalan (HDM) and autologous stem cell transplant (ASCT) is standard of care for multiple myeloma (MM), but there is significant variability in melphalan exposure (area under the plasma drug concentration–time curve, AUC) when using body surface area‐based dosing. Our aim was to es...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Sweiss, Karen, Vemu, Bhaskar, Hofmeister, Craig C., Wenzler, Eric, Calip, Gregory Sampang, Galvin, John P., Mahmud, Nadim, Rondelli, Damiano, Johnson, Jeremy James, Patel, Pritesh
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7576633/
https://ncbi.nlm.nih.gov/pubmed/32285957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14308
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados